Last edition
News about "Sotyktu "
Bristol Myers Squibb Secures EC Approval for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb receives European Commission (EC) approval for Sotyktu to treat active psoriatic arthritis in adults, marking the EU’s first approved TYK2 inhibitor for this indication.
Sotyktu | 12/05/2026 | By News Bureau
US FDA Clears Sotyktu for Active Psoriatic Arthritis
The US Food and Drug Administration (FDA) has approved Sotyktu, developed by Bristol Myers Squibb, for adults with active psoriatic arthritis. The once-daily oral TYK2 inhibitor showed significantly higher ACR20 response rates versus placebo in the phase-III POETYK PsA-1 and PsA-2 trials.
Sotyktu | 07/03/2026 | By News Bureau | 111
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy